[1]
|
S. Shaikh and C. N. Ta, “Evaluation and Management of Herpes Zoster Ophthalmicus,” American Family Physician, Vol. 66, No. 9, 2002, pp. 1723-1730.
|
[2]
|
S. L. Thomas and A. J. Hall, “What Does Epidemiology Tell Us about Risk Factors for Herpes Zoster?” The Lancet Infectious Diseases, Vol. 4, No. 1, 2004, pp. 26-33.
doi:10.1016/S1473-3099(03)00857-0
|
[3]
|
R. W. Johnson, G. Wasner, P. Saddier and R. Baron, “Postherpetic Neuralgia: Epidemiology, Pathophysiology and Management,” Expert Review of Neurotherapeutics, Vol. 7, No. 11, 2007, pp. 1581-1595.
doi:10.1586/14737175.7.11.1581
|
[4]
|
K. Schmader, “Herpes Zoster in Older Adults,” Clinical Infectious Diseases, Vol. 32, No. 10, 2001, pp. 1481-1486.
doi:10.1086/320169
|
[5]
|
M. Vázquez and E. D. Shapiro, “Varicella Vaccine and Infection with Varicella-Zoster Virus,” The New England Journal of Medicine, Vol. 352, No. 5, 2005, pp. 439-440.
doi:10.1056/NEJMp048320
|
[6]
|
K. Galil, P. W. Choo, J. G. Donahue and R. Platt, “The Sequelae of Herpes Zoster,” Archives of Internal Medicine, Vol. 157, No. 11, 1997, pp. 1209-1213.
doi:10.1001/archinte.1997.00440320105010
|
[7]
|
R. E. Hope-Simpson, “Postherpetic Neuralgia,” The Journal of the Royal College of General Practitioners, Vol. 25, No. 157, 1975, pp. 571-575.
|
[8]
|
W. J. Edmunds, M. Brisson and J. D. Rose, “The Epidemiology of Herpes Zoster and Potential Cost-Effectiveness of Vaccination in England and Wales,” Vaccine, Vol. 19, No. 23-24, 2001, pp. 3076-3090.
doi:10.1016/S0264-410X(01)00044-5
|
[9]
|
S. Helgason, G. Petursson, S. Gudmundsson and J. A. Sigurdsson, “Prevalence of Postherpetic Neuralgia after a First Episode of Herpes Zoster: Prospective Study with Long Term Follow up,” British Medical Journal, Vol. 321, No. 7264, 2000, pp. 794-796.
doi:10.1136/bmj.321.7264.794
|
[10]
|
A. L. Cunningham, J. Breuer, D. E. Dwyer, D. W. Gronow, R. D. Helme, J. C. Litt, M. J. Levin and C. R. Macintyre, “The Prevention and Management of Herpes Zoster,” Medical Journal of Australia, Vol. 188, No. 3, 2008, pp. 171-176
|
[11]
|
D. Pavan-Langston, “Ophtalmic Zoster,” In A. M. Arvin and A. A. Gershon, Eds., Varicella-Zoster Virus—Virology and Clinical Management, Cambridge University Press, Cambridge, 2000, pp. 276-298.
doi:10.1017/CBO9780511601194.016
|
[12]
|
W. Opstelten and M. J. Zaal, “Managing Ophthalmic Herpes Zoster in Primary Care,” British Medical Journal, Vol. 331, No. 7509, 2005, pp. 147-151.
doi:10.1136/bmj.331.7509.147
|
[13]
|
W. P. Carter 3rd, C. A. Germann and M. R. Baumann, “Ophthalmic Diagnoses in the ED: Herpes Zoster Ophthalmicus,” The American Journal of Emergency Medicine, Vol. 26, No. 5, 2008, pp. 612-627.
doi:10.1016/j.ajem.2007.08.013
|
[14]
|
Schmader et al., “Study to Evaluate the Safety and Effectiveness of Zostavax? in Subjects 50-59 Years of Age (V211-022),” Clinical Infectious Diseases, Vol. 54, No. 7, 2012, pp. 922-928.
http://clinicaltrials.gov/ct2/show/results/NCT00534248?term=Zostavax&rank=2
|
[15]
|
A. Gil, R. Gil, A. Alvaro, M. S. Martín and A. González, “Burden of Herpes Zoster Requiring Hospitalization in Spain during a Seven-Year Period (1998–2004),” BMC Infectious Diseases, Vol. 9, No. 55, 2009.
doi:10.1186/1471-2334-9-55
|
[16]
|
Ministerio de Sanidad y Consumo, “Clasificación Internacional de Enfermedades 9 Revisión, Modificación clínica,” 1996, pp. 375-376.
http://www.msc.es/estadEstudios/estadisticas/normalizacion/clasifEnferm/instrucNorma.htm
|
[17]
|
Instituto Nacional de la Salud, “Subdirección General de Coordinación Administrativa. Conjunto Mínimo Básico de Datos. Hospitales del INSALUD2001. Madrid 2002,” 2010. http://www.ingesa.msc.es/
|
[18]
|
C. A. Rivero, “El Conjunto Mínimo Básico de Datos en el SNS: Inicios y Desarrollo Actual,” Revista Fuentes Estadísticas, Vol. 49, 2000, pp. 18-19.
http://www.ingesa.msc.es/estadEstudios/documPublica/pdf/grds-2001.pdf
|
[19]
|
J. Schrey?gg, T. Stargardt, O. Tiemann and R. Busse, “Methods to Determine Reimbursement Rates for Diagnosis Related Groups (DRG): A Comparison of Nine European Countries,” Health Care Management Science, Vol. 9, No. 3, 2006, pp. 215-223.
doi:10.1007/s10729-006-9040-1
|
[20]
|
T. J. Liesegang, “Herpes Zoster Ophthalmicus Natural History, Risk Factors, Clinical Presentation, and Morbidity,” Ophthalmology, 115, Suppl. 2, 2008, pp. S3-S12.
doi:10.1016/j.ophtha.2007.10.009
|
[21]
|
P. LaRussa, “The Success of Varicella Vaccine,” Pediatric Annals, Vol. 31, No. 11, 2002, pp. 710-715.
|
[22]
|
J. C. Bramley and I. G. Jones, “Epidemiology of Chickenpox in Scotland: 1981 to 1998,” Communicable Disease and Public Health, Vol. 3, 4, 2000, pp. 282-287.
|
[23]
|
B. P. Yawn, P. Saddier, P. C. Wollan, J. L. St. Sauver, M. J. Kurland and L. Sy, “A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster before Zoster Vaccine Introduction,” Mayo Clinic Proceedings, Vol. 82, No. 11, 2007, pp. 1341-1349.
doi:10.4065/82.11.1341
|
[24]
|
C. M. García, J. Castilla, Y. Montes, J. Morán, A. Salaberri, F. Elía, Y. Floristán, I. Rodrigo, F. Irisarri, M. Arriazu, A. Zabala and A. Barricarte, “Incidencia de la Varicela y el Herpes Zoster Antes de la Introducción de la Vacunación Sistemática Infantil en Navarra, 2005-2006,” Anales del Sistema Sanitario de Navarra, Vol. 31, 2008, pp. 71-80.
|
[25]
|
N. Pérez-Farinós, M. Ordobás, C. García-Frenández, L. García-Comas, S. Ca?ellas, I. Rodero, A. Gutiérrez-Rodríguez, J. García-Gutiérrez and R. Ramírez, “Varicella and Herpes Zoster in Madrid, Based on the Sentinel General Practitioner Network: 1997-2004,” BMC Infectious Diseases, Vol. 7, No. 59, 2007.
doi:10.1186/1471-2334-7-59
|
[26]
|
R. Insinga, R. F. Itzler, J. M. Pellissier, P. Saddier and A. A. Nikas, “The Incidence of Herpes Zoster in a United States Administrative Database,” Journal of General Internal Medicine, Vol. 20, No. 8, 2005, pp. 748-753.
doi:10.1111/j.1525-1497.2005.0150.x
|
[27]
|
A. Gautier, J. Breuer, D. Carrington, M. Martin and V. Rèmy, “Epidemiology and Cost of Herpes Zoster and Post-Herpetic Neuralgia in the United Kingdom,” Epidemiology & Infection, Vol. 137, No. 1, 2009, pp. 38-47.
doi:10.1017/S0950268808000678
|
[28]
|
Ch. Chidiac, J. Bruxelle, J. P. Daures, T. Hoang-Xuan, P. Morel, A. Leplège, A. El Hasnaoui and C. de Labareyre, “Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France,” Clinical Infectious Diseases, Vol. 33, No. 1, 2001, pp. 62-69.
doi:10.1086/320884
|
[29]
|
W. Opstelten, G. A. Van Essen, F. Schellevis, T. Verheij and K. Moons, “Gender as Independent Risk Factor for Herpes Zoster: A Population Based Study,” Annals of Epidemiology, Vol. 16, No. 9, 2006, pp. 692-695.
doi:10.1016/j.annepidem.2005.12.002
|
[30]
|
D. M. Fleming, K. W. Cross, W. A. Cobb and R. S. Chapmna, “Gender Difference in the Incidence of Shingles,” Epidemiology & Infection, Vol. 132, No. 1, 2004, pp. 1-5. doi:10.1017/S0950268803001523
|
[31]
|
B. Law, C. Fitzsimon, L. Ford-Jones, N. MacDonald, P. Dèry and W. Vaudry, “Cost of Chickenpox in Canada: Part I. Cost of Uncomplicated Cases,” Pediatrics, Vol. 104, No. 1, 1999, pp. 1-6. doi:10.1542/peds.104.1.1
|
[32]
|
E. Somekh, I. Dalal, T. Shohat, G. M. Ginsberg and O. Romano, “The Burden of Uncomplicated Cases of Chickenpox in Israel,” Journal of Infection, Vol. 45, No. 4, 2002, pp. 233-236. doi:10.1053/jinf.2002.1039
|
[33]
|
M. Brisson, W. J. Edmunds, N. J. Gay, B. Law and G. De Serres, “Modelling the Impact of Immunization on the Epidemiology of Varicella Zoster Virus,” Epidemiology and Infection, Vol. 125, No. 3, 2002, pp. 651-669.
doi:10.1017/S0950268800004714
|
[34]
|
M. Salleras, et al., “Contacts with Children and Young People and Adult Risk of Suffering Herpes Zoster,” Vaccine, Vol. 29, No. 44, 2011, pp. 7602-7605.
doi:10.1016/j.vaccine.2011.08.023
|
[35]
|
J. M. Guillen, R. Gil-Prieto, A. Alvaro and A. Gil, “Burden of Adult Varicella Hospitalizations in Spain (2001-2007),” Human Vaccines and Immunotherapeutics, Vol. 6, No. 8, 2010, pp. 659-663. doi:10.4161/hv.6.8.12014
|
[36]
|
A. S. Gurwood, J. Savochka and B. J. Sirgany, “Herpes Zoster Ophthalmicus,” Optometry, Vol. 73, No. 5, 2002, pp. 295-230.
|
[37]
|
Zostavax SmPC, 2011.
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf
|
[38]
|
S. Peiro and J. Librero, “Evaluación de la Calidad a Partir del Conjunto Mínimo de Datos Básicos al Alta Hospitalaria,” Revista de Neurología, Vol. 29, 1999, pp. 651-661.
|
[39]
|
Ministerio de Sanidad y Consumo, “Análisis y Desarrollo de los GDR en el Sistema Nacional de Salud,” 2010.
www.msc.es/estadEstudios/estadisticas/docs/analisis.pdf
|